

### Transcript Details

This is a transcript of a continuing medical education (CME) activity. Additional media formats for the activity and full activity details (including sponsor and supporter, disclosures, and instructions for claiming credit) are available by visiting:

<https://reachmd.com/programs/cme/it-all-starts-with-a-patient/26254/>

Released: 06/13/2024

Valid until: 06/13/2025

Time needed to complete: 56m

### ReachMD

[www.reachmd.com](http://www.reachmd.com)

[info@reachmd.com](mailto:info@reachmd.com)

(866) 423-7849

---

### It All Starts With a Patient

#### Announcer:

Welcome to CME on ReachMD. This episode is part of our MinuteCE curriculum.

Prior to beginning the activity, please be sure to review the faculty and commercial support disclosure statements as well as the learning objectives.

#### Jeff McIntyre:

This is CME on ReachMD. Hi, and welcome to Endocrinologists and PCPs: The Frontline Defense Against Cirrhosis in Patients with Type 2 Diabetes, provided in partnership by Global Learning Collaborative, Global Liver Institute, and the Cardiometabolic Center Alliance. I'm Jeff McIntyre, the Vice President for Liver Health Programs with the Global Liver Institute. The mission of the Global Liver Institute is to improve the lives of individuals and families impacted by liver disease through promoting innovation, encouraging collaboration, and scaling optimal approaches to help eradicate liver diseases, and this is why we are excited to collaborate with the Global Learning Collaborative on this certified activity for physicians, nurses, and pharmacists on fatty liver disease.

At the Global Liver Institute, it all starts with the patient. We save lives by empowering patient advocates to collaborate with policymakers, clinicians, and industry to drive the liver health field forward. It is our vision for liver health awareness to be universal and for liver diseases to take their proper place on the global public health agenda consistent with their prevalence and its impact. We strive daily to uphold our core values at GLI. We solve problems that matter to patients in ways that are both equitable and efficient.

Liver disease is a chronic and progressive disease that impacts billions and millions around the world. Roughly 1.5 billion individuals suffer from some sort of liver disease, resulting in almost 2 million deaths per year caused by liver conditions globally, and, unfortunately, this number is rising.

When we look at obesity specifically, almost 2 billion individuals suffer from obesity worldwide, 400 million of those have diabetes. Both of these are incredibly high risk factors for MASLD and MASH, and liver cancer; that is often manifested in these adverse outcomes: cirrhosis, liver cancer, bariatric procedures, liver transplant, and death. As such, we are pleased and honored to be joined by our esteemed faculty to lead you through this CME today: Naim Alkhouri, Tessa Janovsky, and Robert Eckel, three of the real leaders in the field of addressing liver health and liver disease.

So in closing, I want to thank you for joining this course and joining me today. It is vitally important that providers are able to stay up to date on the latest innovations in fatty liver disease and liver disease in general. So, thank you. We're happy to collaborate with the Global Learning Collaborative on this important initiative for endocrinologists and PCPs on the frontline defense against cirrhosis in patients with type 2 diabetes, and we continue to look forward to the good work fighting for liver patients and against fatty liver disease worldwide. Thank you.

#### Announcer:

You have been listening to CME on ReachMD. This activity is provided by Medtelligence and is part of our MinuteCE curriculum.

To receive your free CME credit, or to download this activity, go to [ReachMD.com/Medtelligence](http://ReachMD.com/Medtelligence). Thank you for listening.

